Small-Cap Biotech M&A, via the Internet
Executive Summary
Robert Naismith, CEO of eMed Securities, a private investment banking firm, has just sold tiny, troubled American biotech firm Cistron to Celltech in the UK--via the Internet. Naismith put a lot of work into building a case that Cistron's science was good, even if its corporate history was less than sterling. Then he e-mailed letters tailored to different types of potential buyers and watched the information he'd posted on his firm's web site get 30,000 hits in the two weeks. EMed intends to keep on leveraging the Internet, not only to promote M&A of small-cap life science companies, but to help those firms attract retail capital. On-line roadshows are on the way, he says.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.